Symbol="ADCT"
AssetType="Common Stock"
Name="ADC Therapeutics SA"
Description="ADC Therapeutics SA, a biotechnology company focused on clinical stage oncology, develops Antibody Drug Conjugates (ADC) for patients suffering from hematologic malignancies and solid tumors. The company is headquartered in Epalinges, Switzerland."
CIK="1771910"
Exchange="NYSE"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="BIOPOLE, ROUTE DE LA CORNICHE 3B, EPALINGES, CH"
FiscalYearEnd="September"
LatestQuarter="2023-03-31"
MarketCapitalization="119351000"
EBITDA="-133529000"
PERatio="None"
PEGRatio="None"
BookValue="0.466"
DividendPerShare="0"
DividendYield="0"
EPS="-2.28"
RevenuePerShareTTM="2.305"
ProfitMargin="-1.089"
OperatingMarginTTM="-0.738"
ReturnOnAssetsTTM="-0.16"
ReturnOnEquityTTM="-1.982"
RevenueTTM="182402000"
GrossProfitTTM="35098000"
DilutedEPSTTM="-2.28"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="-0.592"
AnalystTargetPrice="8.33"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="1.641"
PriceToBookRatio="2.579"
EVToRevenue="0.0382"
EVToEBITDA="-0.0402"
Beta="1.033"
num_52WeekHigh="10.82"
num_52WeekLow="1.218"
num_50DayMovingAverage="2.064"
num_200DayMovingAverage="3.098"
SharesOutstanding="80642000"
DividendDate="None"
ExDividendDate="None"
symbol="ADCT"
open="1.49"
high="1.51"
low="1.39"
price="1.49"
volume="340166.00"
latest_trading_day="2023-08-02"
previous_close="1.51"
change="-0.02"
change_percent="-1.3245%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="79"
trend_strength="Absent or Weak Trend"
buying_signal="Strong Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="21"
Volume_recent_avg="572171"
Change_recent_avg="-0.01"
Delta_recent_avg="0.14"
Variance_recent_avg="0.07"
Change_ratio_recent_avg="-0.54"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="21"
Aroon_momentum_negative="79"
image_negative_thumbnail_id_1="1144"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0177.jpeg"
image_negative_thumbnail_id_2="508"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0097.jpeg"
image_neutral_thumbnail_id_1="578"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0021.jpeg"
image_neutral_thumbnail_id_2="590"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0009.jpeg"
image_positive_thumbnail_id_1="602"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0106.jpeg"
image_positive_thumbnail_id_2="703"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0005.jpeg"
image_professor_thumbnail_id_1="1195"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0029.jpeg"
image_professor_thumbnail_id_2="1197"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0031.jpeg"
